✦ LIBER ✦

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

✍ Scribed by Kappos, Ludwig; Radue, Ernst-Wilhelm; O'Connor, Paul; Polman, Chris; Hohlfeld, Reinhard; Calabresi, Peter; Selmaj, Krzysztof; Agoropoulou, Catherine; Leyk, Malgorzata; Zhang-Auberson, Lixin; Burtin, Pascale

Book ID: 121843958
Publisher: Massachusetts Medical Society
Year: 2010
Tongue: English
Weight: 367 KB
Volume: 362
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa0909494

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral Fingolimod (FTY720) for Relapsing M

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

✍ Kappos, Ludwig; Antel, Jack; Comi, Giancarlo; Montalban, Xavier; O'Connor, Paul; 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 297 KB

A Randomized, Placebo-Controlled Trial o

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

✍ Polman, Chris H.; O'Connor, Paul W.; Havrdova, Eva; Hutchinson, Michael; Kappos, 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 211 KB

Placebo-Controlled Trial of Oral Laquini

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

✍ Comi, Giancarlo; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Ale 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 602 KB

Effects of fingolimod in relapsing-remit

Effects of fingolimod in relapsing-remitting multiple sclerosis

✍ Sorensen, Per Soelberg 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 45 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

## Background: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. we aimed to assess efficacy and safety of two dose regimens of the humanised anti-cd20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ## Methods: We did a multicentre,